Septerna, Inc. Files 8-K Report

Ticker: SEPN · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1984086

Sentiment: neutral

Topics: sec-filing, 8-k, disclosure

TL;DR

Septerna filed an 8-K, likely with financial updates. Watch for details.

AI Summary

On January 13, 2025, Septerna, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events beyond the filing itself were detailed in the provided text.

Why It Matters

This filing indicates Septerna, Inc. is providing updates or disclosures to the SEC, which could contain material information for investors.

Risk Assessment

Risk Level: low — The filing is a standard procedural disclosure without immediate negative or positive financial implications mentioned.

Key Players & Entities

FAQ

What specific information is disclosed in the Regulation FD section of this 8-K?

The provided text does not specify the content of the Regulation FD disclosure, only that it is part of the filing.

Are there any financial statements included with this 8-K filing?

Yes, the filing is listed as including 'Financial Statements and Exhibits'.

What is Septerna, Inc.'s primary business according to the filing?

Septerna, Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]' according to its Standard Industrial Classification.

When was Septerna, Inc. incorporated?

Septerna, Inc. was incorporated in Delaware.

What is the SEC file number for Septerna, Inc.?

The SEC file number for Septerna, Inc. is 001-42382.

Filing Stats: 515 words · 2 min read · ~2 pages · Grade level 9.5 · Accepted 2025-01-13 06:07:13

Key Financial Figures

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits 99.1 Corporate Presentation of Septerna, Inc., dated January 2025, furnished herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Septerna, Inc. Date: January 13, 2025 By: /s/ Jeffrey Finer, M.D., Ph.D. Jeffrey Finer, M.D., Ph.D. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing